title: Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors.
abstract: Src family kinases (SFKs) have been implicated in resistance to both radiation and epidermal growth factor receptor (EGFR) inhibition. Therefore, we investigated whether inhibition of SFK through dasatinib (DSB) can enhance the effect of radiotherapy in two in vivo human head and neck squamous cell carcinoma (HNSCC) models. Response to DSB and/or radiotherapy was assessed with tumor growth delay assays in two HNSCC xenograft models, SCCNij153 and SCCNij202. Effects on EGFR signaling were evaluated with Western blot analysis, and effects on DNA repair, hypoxia, and proliferation were investigated with immunohistochemistry. DSB and radiotherapy induced a significant growth delay in both HNSCC xenograft models, although to a lesser extent in SCCNij202. DSB did not inhibit phosphorylated protein kinase B (pAKT) or phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2) but did inhibit (phosphorylated) DNA-dependent protein kinase. Moreover, DSB reduced repair of radiation-induced DNA double-strand breaks as shown by an increase of p53-binding protein 1 (53BP1) staining 24 hours after radiation. This effect on DNA repair was only observed in the cell compartment where phosphorylated SFK (pSFK) was expressed: for SCCNij153 tumors in both normoxic and hypoxic areas and for SCCNij202 tumors only in hypoxic areas. No consistent effects of DSB on hypoxia or proliferation were observed. In conclusion, DSB enhances the effect of radiotherapy in vivo by inhibition of radiation-induced DNA repair and is a promising way to improve outcome in HNSCC patients.
authors.affiliation: Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
authors.forename: Hanneke
authors.initials: H
authors.lastname: Stegeman
authors.forename: Paul N
authors.initials: PN
authors.lastname: Span
authors.forename: Paul F J W
authors.initials: PF
authors.lastname: Rijken
authors.forename: Simone C
authors.initials: SC
authors.lastname: Cockx
authors.forename: Deric L
authors.initials: DL
authors.lastname: Wheeler
authors.forename: Mari
authors.initials: M
authors.lastname: Iida
authors.forename: Albert J
authors.initials: AJ
authors.lastname: van der Kogel
authors.forename: Johannes H A M
authors.initials: JH
authors.lastname: Kaanders
authors.forename: Johan
authors.initials: J
authors.lastname: Bussink
references.citation: Clin Cancer Res. 2008 Jul 1;14(13):4284-91
references.pmid: 18594011
references.citation: Cancer Res. 2004 Sep 1;64(17):6166-73
references.pmid: 15342401
references.citation: Int J Cancer. 2009 Jan 15;124(2):280-6
references.pmid: 18924149
references.citation: Cancer. 2011 May 15;117(10):2112-9
references.pmid: 21523723
references.citation: Mol Cell Biol. 2011 Apr;31(8):1719-33
references.pmid: 21300785
references.citation: Eur J Epidemiol. 2005;20(7):575-9
references.pmid: 16119429
references.citation: Radiother Oncol. 2013 Mar;106(3):383-9
references.pmid: 23453541
references.citation: Radiother Oncol. 2010 Nov;97(2):330-7
references.pmid: 20667610
references.citation: Exp Cell Res. 2009 Sep 10;315(15):2658-72
references.pmid: 19505457
references.citation: Clin Cancer Res. 2011 Sep 1;17(17):5546-52
references.pmid: 21670084
references.citation: Nat Rev Cancer. 2004 Jun;4(6):470-80
references.pmid: 15170449
references.citation: Cancer Biol Ther. 2009 Apr;8(8):696-703
references.pmid: 19276677
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544
references.citation: BMC Cancer. 2012 Oct 10;12:463
references.pmid: 23046567
references.citation: Nat Rev Genet. 2006 Jan;7(1):45-54
references.pmid: 16369571
references.citation: J Signal Transduct. 2012;2012:483796
references.pmid: 22988500
references.citation: Oncogene. 2009 Oct 29;28(43):3801-13
references.pmid: 19684613
references.citation: Int J Radiat Biol. 2007 Nov-Dec;83(11-12):781-91
references.pmid: 18058366
references.citation: Clin Cancer Res. 2012 Jan 1;18(1):127-39
references.pmid: 22090359
references.citation: J Biol Chem. 1999 Mar 19;274(12):8335-43
references.pmid: 10075741
references.citation: Mol Cancer Res. 2008 Dec;6(12):1872-80
references.pmid: 19074832
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32
references.pmid: 16203784
references.citation: Br J Cancer. 1998;77(1):57-64
references.pmid: 9459146
references.citation: J Cancer Sci Ther. 2009 Nov 30;1(2):52-61
references.pmid: 20505783
references.citation: Cancer Res. 2002 Dec 15;62(24):7350-6
references.pmid: 12499279
references.citation: Radiother Oncol. 2012 Nov;105(2):241-9
references.pmid: 23010482
references.citation: Radiother Oncol. 2005 Aug;76(2):157-61
references.pmid: 16024112
references.citation: J Biol Chem. 2005 Sep 2;280(35):31182-9
references.pmid: 16000298
references.citation: Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):571-82
references.pmid: 10974478
references.citation: Neoplasia. 2012 Jun;14(6):463-75
references.pmid: 22787428
references.citation: Cancer Metastasis Rev. 2003 Dec;22(4):337-58
references.pmid: 12884910